zurück

Pembrolizumab (new indication: gastric cancer with MSI-H or dMMR tumors, pretreated patients)

 

Subject:

  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Gastric cancer
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 01.08.2022
  • Final decision by G-BA: 19.01.2023

 

Final decision:

  1. Adults with disease progression during or after therapy: Hint for a non-quantifiable additional benefit
  2. Adults with disease progression during or after at least two previous therapies: No additional benefit proved